Long-acting injectable risperidone

Annals of Pharmacotherapy

Volumn 38, Issue 12, 2004, Pages 2122-2127

  Ehret, Megan J ^a   Fuller, Matthew A ^a,b,c,d  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF TOLEDO   (United States)

^d Louis Stokes Cleveland Vet Aff M   (United States)

Author keywords

Long acting risperidone; Schizophrenia

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 2D6; FLUPHENAZINE; HALOPERIDOL; LONG ACTING DRUG; PALIPERIDONE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; RISPERIDONE;

AKATHISIA; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STORAGE; DYSPEPSIA; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERSALIVATION; INJECTION; INSOMNIA; PARKINSONISM; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REVIEW; RHINITIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; STROKE; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAMUSCULAR; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; SCHIZOPHRENIA;

EID: 12844251255     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E085     Document Type: Review

References (29)

1. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7.
2. Davis JM. Overview. Maintenance therapy in psychiatry, 1: schizophrenia. Am J Psychiatry 1975;132:1237-45.
3. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID. Relapse and rehospitalization during maintenance treatment of schizophrenia. Arch Gen Psychiatry 1997;54:453-64.
4. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.
5. Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm 1998;55:17-9.
6. Lasser RA, Ramstack JM, Grandolfi GP, Mannaert E, Hoore PD. Long-acting injectable risperidone [Risperdal Consta]: manufactured using Medisorb microsphere technology, pharmacokinetics, and injection site assessments (poster). Presented at: International Congress of Schizophrenia Research, Colorado Springs, CO, March 29-April 2, 2003.
7. Package insert. Risperdal Consta (risperidone). Titusville, NJ: Janssen, October 2003.
8. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoech E, Van Beijsterveldt L. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55:13-7.
9. Diagnostic and statistical manual of mental disorders. 4th revision. Washington, DC: American Psychiatric Association, 1994.
10. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32.
11. Fleischhacker WW, Eerdekens M, Kancher K, Remington G, Llorca PM, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-7.
12. Schooler NR. Relapse and rehospitalization: comparing oral and depot antispsychotics. J Clin Psychiatry 2003;64(suppl 16):14-7.
13. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets (poster). Presented at: 11th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, February 24-March 1, 2002.
14. Turner M, Eerdekens M, Jacko M, Eerdekens E. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004;19:241-9.
15. Kane J, Gharabawi G, Bossie CA, Zhu Y, Lasser RA. Effect of a novel long-acting antipsychotic formulation in stable patients with schizoaffective disorder (poster). Presented at: 41st Annual American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8-12, 2002.
16. Canuso C, Bossie C, Zhu Y, Lasser R, Falkai P. Long-acting risperidone reduces symptoms of depression and anxiety in stable patients with schizophrenia and schizoaffective disorder (poster). Presented at: 5th Annual International Congress on Bipolar Disorder, Pittsburgh, PA, June 12-14, 2003.
17. Lasser R, Kosik-Gonzalez C, Bossie C, Gharabawi G. Long-term treatment of bipolar disorder: consideration of the current state and future directions (poster). Presented at: 5th Annual International Congress on Bipolar Disorder, Pittsburgh, PA, June 12-14, 2003.
18. Marder SR, Conley R, Ereshefsky L, Kane JM, Turner MS. Dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 2003;64(suppl 16):41-6.
19. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinex RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150-5.
20. Bossie CA, Lasser RA, Gharabawi G. Low or absent pain and injectable site effects with long-acting risperidone (poster). Presented at: 156th Annual American Psychiatric Association Meeting, San Francisco, May 17-22, 2003.
21. Canuso CM, Bossie CA, Lasser RA, Gharabawi G. Reduced serum prolactin levels after treatment with long-acting risperidone (poster). Presented at: 156th Annual American Psychiatric Association Meeting, San Francisco, May 17-22, 2003.
22. Kleinberg DL, Davis JM, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57-61.
23. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22.
24. Nasrallah HA, Duchesne I, Mehnert A, Janagap C. Long-acting risperidone injection improves quality of life. J Clin Psych 2004;65(4):531-6.
25. Remington G, Devos E, Eerdekens M, Duchesne I, Leal A, Mehnert A. Treatment with long-acting risperidone injection reduces healthcare resource use (poster). Presented at: 13th Annual Collegium Internationale Neuro-Psychopharmacologicum Congress, Montreal, Canada, June 23-27, 2002.
26. Kane JM, Leucht S, Carpenter D, Docherty JP. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(suppl 12):1-100.
27. 2004 Drug topics red book. Montvale, NJ: Thompson PDR, 2004.
28. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004;19:219-25.
29. Van os J, Bossie CA, Laser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004;19:229-32.